ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
about
Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniaeGenome-wide characterisation of the binding repertoire of small molecule drugs.Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniaeNovel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolatesPrevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seFluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactionsNew mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.Activity of and resistance to moxifloxacin in Staphylococcus aureus.ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniaeActivities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniaeFluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006.In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.Fluoroquinolone resistance in Streptococcus dysgalactiae subsp. equisimilis and evidence for a shared global gene pool with Streptococcus pyogenes.Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
P2860
Q24801022-4377123F-8905-4A9B-81B3-E9FA1D13753EQ33209914-FC578622-3505-43D5-8404-83F9891329D9Q33594174-8E23E89B-3E87-403C-A434-4BDF378E87C7Q33757558-051681EE-0D6A-4134-B90F-49569D6BB7BDQ33836603-DC823DB5-EA17-4762-A1F1-027DBAEE8C29Q33978849-B3BFF68E-E363-494B-B459-F27A3766F60DQ33980313-C9F5646A-1FD8-42C9-AD26-DB8856C1FF3BQ33980689-C901A287-3D58-4680-82CE-FDA1EA5BE711Q33980747-A234FB55-1008-4390-BADA-65DB95875211Q33980991-C931759C-68C4-4D14-BA23-3D615718E8DAQ33981750-C9B67860-5CA0-490B-A15C-AC9E0096F0B6Q33983092-7147B427-1E19-4EB4-9B45-B49356AF7A9AQ33983660-D0E76CF7-F275-4498-B0F3-D3E001F655C8Q34142238-BBADC99C-EC20-4CB7-B845-5737CF5D8F4AQ34352053-EF8D3EFE-2A3F-4306-B284-7FA9E389F505Q34885313-FFD471A1-BBE1-4247-83AD-393D5CEE42B0Q36474350-DC9701B3-2EA6-4C54-907A-E846BAA50D8FQ36669771-6166B437-8BCA-4A8B-B8C0-0C10A9E498FEQ39465570-20379866-B4C5-4730-B8ED-0C93485ACEC4Q39475328-F62AD81F-7C4F-4257-8C44-D60F1DF6F129Q39476686-5C97DBAB-011C-42B7-B865-1DD3077A9D1AQ39477371-865F8EDF-749A-4D40-ABB1-EFE802FC7275Q39478033-43848CA2-81FC-4323-9C5D-25ECC96329D8Q39478563-354BDFF7-C683-47E5-9CE9-4D06F5C31483Q39651301-7C5665A3-5CDD-41D0-BB53-EB2DFC6440AAQ39652363-8DB611CE-A578-4E96-AA84-FA8C9DC51261Q39682438-EC59F2BC-8BA4-4F32-BCD5-FA70B0AD7B24Q40130516-DEC472B7-3F53-4BB5-A5D3-2F06381343F0Q40334880-6F63B381-D13E-413C-BB9A-9FEBF72A70A0Q40705759-FD3B9DFF-A027-4C2B-9051-4FBD9DB685F9Q41854694-2E6DCD6E-78F2-41CB-A8C0-AF97710C1A88Q43063844-7C548940-DFEA-4E2A-BE0E-54D72BADCB1E
P2860
ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@ast
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@en
type
label
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@ast
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@en
prefLabel
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@ast
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@en
P2093
P2860
P1476
ParC and GyrA may be interchan ...... s in Streptococcus pneumoniae.
@en
P2093
P2860
P304
P407
P577
1999-02-01T00:00:00Z